Hook:
A Nasdaq-listed insurtech stock trading at $0.87 per share wants to sell $220 million in new equity to buy Bitcoin. Let that sink in. This isn't MicroStrategy 2.0. It's a Hail Mary from a company with a market cap hovering around $30 million. The proposal — disclosed in a sparse filing — has no hedging strategy, no custody details, and no timeline. Verification precedes valuation; always. So I ran my protocol.
Context:
Zhibao Technology Inc. is a Shanghai-based insurance technology firm that went public in the U.S. via a SPAC merger in 2022. Since then, its stock has lost over 90% of its value. The company now faces a Nasdaq minimum bid price compliance deadline in June 2025. On March 10, 2025, the Board authorized a plan to issue up to $220 million in new common stock and use the proceeds — or directly issue shares in exchange — to acquire Bitcoin.
This is not novel. MicroStrategy normalized the "Bitcoin Treasury" narrative. But MicroStrategy has a profitable enterprise software business, a founder with deep pockets, and a stock that trades at a premium. Zhibao has none of the above. Its core insurtech operations generated negative free cash flow in 2024. The company is essentially asking investors to fund a leveraged bet on Bitcoin's price appreciation — with zero downside protection.
Core: Deconstructing the Dilution Spiral
Let me break this down with a simple model. Assume Zhibao has 35 million shares outstanding at $0.87 = $30.5 million market cap. To raise $220 million, it must issue approximately 253 million new shares — diluting existing shareholders by 88%. After the raise, the company holds $220 million in Bitcoin and has a fully diluted market cap of ~$250 million. The Bitcoin-to-market-cap ratio would be 88%, dwarfing MicroStrategy's current ratio (around 30% as of Q1 2025).
Why does this matter? Because if Bitcoin drops 30% — to $56,000 from current $80,000 — Zhibao's Bitcoin holdings would be worth $154 million, while its market cap could theoretically collapse below that as confidence evaporates. The stock becomes a pure Bitcoin volatility derivative with negative convexity. Based on my 2022 Terra liquidity crunch playbook, I know that when equity is used as rocket fuel for a volatile asset, the liquidation cascade is brutal. No circuit breakers. No stablecoin buffer.
Now examine execution risk. The offering is structured "at-the-market" (ATM) or via direct placement. For a sub-$1 stock, institutional appetite is near zero. Retail may bite, but the SEC will scrutinize the prospectus under Rule 415 (shelf offerings) and possibly require a shareholder vote. In my 2017 ICO audit protocol, I flagged projects with unclear tokenomics — Zhibao's plan is similarly opaque: no custodian named, no insurance, no disclosure of sale lockups. The probability of full funding? I estimate below 20% based on historical low-priced stock offerings of similar magnitude.
Contrarian: The Smart Money Stays Away
Mainstream crypto media will frame this as "another public company adding Bitcoin to treasury." The contrarian truth is: this is a distressed asset in disguise. Smart money — the funds that piled into MSTR, COIN, and GBTC — won't touch Zhibao because the leverage is on the issuer side, not the balance sheet. The risk-reward is asymmetric: if Bitcoin goes to $150k, Zhibao's stock might 2x or 3x from a severely diluted base. If Bitcoin goes to $40k, the stock goes to zero. That's a 1:5 upside-downside ratio in a best-case scenario.
Moreover, the narrative of "Bitcoin as reserve asset" gets polluted when companies use it as a lifeline. Regulatory blowback could intensify. The SEC has already signaled hostility toward crypto-related offerings that resemble securities fraud. In 2024, the SEC charged a shell company for misleading investors about crypto holdings. Zhibao's filing lacks basic risk disclaimers about Bitcoin volatility. I flagged this in my 2023 ZK-Rollup audit — when documentation is thin, the protocol is broken.
Takeaway: This Is a Signal, Not a Trade
The only actionable takeaway is a non-trade. Watch the EDGAR filing for a Form 424B5 prospectus. If that hits, the probability of execution rises to 40%. But even then, the fundamental question remains: why would a cash-burning insurtech company bet its survival on an asset class it has no competitive advantage in trading? The answer is desperation. Chop is for positioning. Right now, the chop is telling me to stay out of any stock tied to this deal. The real insight? This could be the first domino of a new trend: zombie firms using Bitcoin to fake a turnaround. If two more follow, we'll have a new systemic risk in the crypto equity space — and I'll be building a short basket.
Verification precedes valuation; always.
